MyFinsight
Home
Blog
About
Contact
Download
Download image
Net change in cash
and cash...
-$14,678,403
Stock-based compensation
$575,565
Accounts payable and
accrued expenses
$432,207
Depreciation
$91,577
Amortization of right of use
asset
$39,189
Loss on disposal of
fixed assets
-$34,153
Proceeds from the sale of
short-term investments
$3,000,000
Proceeds from exercise of
stock options
$33,532
Net cash used in
operating activities
-$9,827,193
Net cash used in
investing activities
-$4,800,836
Net cash provided by
financing activities
-$37,561
Effect of foreign
currency on cash
-$12,813
Canceled cashflow
$1,172,691
Canceled cashflow
$3,000,000
Canceled cashflow
$33,532
Net loss
-$10,086,687
Purchase of short-term
investments
$7,768,350
Payments of deferred
offering costs
$71,093
Prepaid expenses and
other current assets
$866,595
Operating lease liability
-$35,229
Realized gain on
available-for-sale securities
$10,648
Tax receivable
$725
Purchase of property and
equipment
$32,486
Back
Back
Cash Flow
Immix Biopharma, Inc. (IMMX)
Immix Biopharma, Inc. (IMMX)
source: myfinsight.com